Trial Profile
Study to examine the efficacy of modified treat and extend regimen of aflibercept to central retinal vein occlusion with cystoid macular edema
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Oct 2019
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Central retinal vein occlusion; Retinal oedema
- Focus Therapeutic Use
- 08 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 29 Apr 2017 Status changed from not yet recruiting to recruiting.
- 04 Nov 2016 New trial record